Fengqin Xu

Fengqin Xu


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Pharmacological Research
Verified
Journal Article
Closed access
XLXu Lan
Xu Lan
JZJunnan Zhao
Junnan Zhao
YZYing Zhang
Ying Zhang
YCYao Chen
Yao Chen
YLYue Liu
Yue Liu
FXFengqin Xu
Fengqin Xu

5 July 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
ZQZhongwen Qi
Zhongwen Qi
ZYZhipeng Yan
Zhipeng Yan
YWYueyao Wang
Yueyao Wang
NJNan Ji
Nan Ji
XYXiaoya Yang
Xiaoya Yang
JZJunping Zhang
Junping Zhang
The inflammatory microenvironment after acute myocardial infarction (MI) is a key limiting factor in the clinical application of stem cell transplantation and paracrine exosome therapy. Qishen Yiqi Pills contain a saponin ingredient called Ginsenoside Rh2 (Rh2) which exhibits a certain therapeutic effect on MI. However, the mechanism by which Rh2 alleviates the inflammatory microenvironment and improves the therapeutic efficiency of exosomes remains enigmatic. Here, we found that Rh2 attenuated the adverse effect of oxygen-glucose deprivation (OGD)-induced cellular injury, an in vitro pathological model of MI. Confocal microscopy revealed that DiI-labeled BMSCs-derived exosomes exhibited an increased homing ability of cardiomyocytes, which, in turn, inhibited the nuclear translocation of NF-κB p65 and NLRP3 inflammasome activation, thereby alleviating the inflammatory microenvironment and further facilitating the homing of exosomes to cardiomyocytes by forming a feed-forward enhancement loop. Additionally, we found that Rh2 could regulate the HMGB1/NF-κB signaling pathway to improve the OGD environment of cardiomyocytes, increasing the efficiency of the feed-forward loop. In conclusion, we found that Rh2 can improve the inflammatory microenvironment by enhancing the protection of exosomes against myocardial injury, providing new insights into the indirect modification of exosomes by Rh2 in MI treatment.

23 June 2021 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
YZYan Zhang
Yan Zhang
JMJun Mei
Jun Mei
JLJing Li
Jing Li
YZYing Zhang
Ying Zhang
QZQingbing Zhou
Qingbing Zhou
FXFengqin Xu
Fengqin Xu
Atherosclerotic cardiovascular diseases, in which atherosclerosis (AS) is the main pathologic basis, are currently the primary diseases leading to human deaths. Emerging evidence showed that DNA methylation, which could affect the transcription and expression of critical regulatory genes, has key roles in AS. Aberrant DNA methylation including aberrant hypomethylation and hypermethylation plays key roles in endothelial-cell dysfunction, macrophage inflammation, abnormal proliferation of vascular smooth muscle cells, plaque rupture, and thrombosis in AS. Chinese herbal medicines, including single compounds and formulations, showed light on the treatment of AS through regulating the aberrant DNA methylation in AS. Targeting the aberrant DNA methylation may be one of the most important treatment strategies in the cure and prevention of AS. In this review, we focus on the relationship between DNA methylation and AS, as well as the beneficial effects of Chinese herbal medicines on DNA methylation in AS.

4 June 2024 in Phytomedicine
Verified
Journal Article
Closed access
JMJun Mei
Jun Mei
CJChunxiao Ju
Chunxiao Ju
BWBiqing Wang
Biqing Wang
RGRui Gao
Rui Gao
YZYanhong Zhang
Yanhong Zhang
FXFengqin Xu
Fengqin Xu

1 May 2020 in Annals of Palliative Medicine
Verified
Journal Article
Open access
PDF file
JZJunnan Zhao
Junnan Zhao
XLXu Lan
Xu Lan
YLYue Liu
Yue Liu
YLYanfei Liu
Yanfei Liu
YXYanfang Xian
Yanfang Xian
FXFengqin Xu
Fengqin Xu
Anti-aging role of Chinese herbel medicine: an overview of scientific evidence from 2008 to 2018 Junnan Zhao, Xu Lan, Yue Liu, Yanfei Liu, Yanfang Xian, Zhixiu Lin, Fengqin Xu

28 February 2023 in European Journal of Pharmacology
Verified
Journal Article
Closed access
QZQiuxiao Zhan
Qiuxiao Zhan
JZJunnan Zhao
Junnan Zhao
LLLu Liu
Lu Liu
BWBiqing Wang
Biqing Wang
JHJiaqi Hui
Jiaqi Hui
FXFengqin Xu
Fengqin Xu